Clear Cell Renal Cell Carcinoma: Clinical Trials

3 trials for Clear Cell Renal Cell Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 suspended. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Suspended 3
Phase 21Suspended 1

Follow Clear Cell Renal Cell Carcinoma: new trials by email Literature Review of Clear Cell Renal Cell Carcinoma trials Research Report on Clear Cell Renal Cell Carcinoma

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
68Ga-NYM096 PET/CT and 177Lu-NYM096 - Clear Cell Renal Cell Carcinoma
Phase 1SuspendedPeking Union Medical College Hospital202024-11-212025-12-31
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Phase 1SuspendedCity of Hope Medical Center312023-10-062026-10-08
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
177Lu girentuximab, Nivolumab, Cabozantinib - Advanced Cancer, Clear Cell Renal Cell Carcinoma
Phase 1 / Phase 2SuspendedM.D. Anderson Cancer Center1002023-06-302026-10-08

Narrower conditions

Carcinoma, Renal Cell (3)

Broader conditions

Adenocarcinoma (3)  ·  Carcinoma (3)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Kidney Diseases (3)  ·  Kidney Neoplasms (3)  ·  Male Urogenital Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms by Site (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Urogenital Diseases (3)  ·  Urogenital Neoplasms (3)  ·  Urologic Diseases (3)  ·  Urologic Neoplasms (3)

Interventions

Nivolumab (2)  ·  CTLA-4 Antigen (1)  ·  Ipilimumab (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  cabozantinib (1)

Sponsors

City of Hope Medical Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  Peking Union Medical College Hospital (1)

Countries

United States (2)  ·  China (1)

Top investigators

Eric Jonasch, MD (1)  ·  Li Huo, MD (1)  ·  Sumanta K Pal (1)

NIH funding

P30CA033572 (1)